Pseudomonas aeruginosa infection

On 28 July 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation 387. The active ingredient is amikacin sulfate (liposomal) for treatment of pseudomonas aeruginosa lung infection in cystic fibrosis.